|
IE56026B1
(en)
|
1982-10-19 |
1991-03-27 |
Cetus Corp |
Cysteine-depleted muteins of biologically active proteins
|
|
US4853332A
(en)
|
1982-10-19 |
1989-08-01 |
Cetus Corporation |
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
|
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
|
US4530787A
(en)
|
1984-03-28 |
1985-07-23 |
Cetus Corporation |
Controlled oxidation of microbially produced cysteine-containing proteins
|
|
US4572798A
(en)
|
1984-12-06 |
1986-02-25 |
Cetus Corporation |
Method for promoting disulfide bond formation in recombinant proteins
|
|
US5116943A
(en)
|
1985-01-18 |
1992-05-26 |
Cetus Corporation |
Oxidation-resistant muteins of Il-2 and other protein
|
|
CA1340265C
(en)
|
1985-01-18 |
1998-12-15 |
Kirston E. Koths |
Oxidation resistant muteins
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
US4766106A
(en)
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
|
US4816440A
(en)
|
1985-09-26 |
1989-03-28 |
Cetus Corporation |
Stable formulation of biologically active proteins for parenteral injection
|
|
US5425940A
(en)
|
1986-04-09 |
1995-06-20 |
Cetus Oncology Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
|
US4863727A
(en)
|
1986-04-09 |
1989-09-05 |
Cetus Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
|
US5098702A
(en)
|
1986-04-09 |
1992-03-24 |
Cetus Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
|
US4894226A
(en)
|
1986-11-14 |
1990-01-16 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
|
|
WO1989004665A2
(en)
|
1987-11-25 |
1989-06-01 |
Cetus Corporation |
Treatment of infections caused by a primary immunodeficiency with interleukin-2
|
|
US5066489A
(en)
|
1988-03-28 |
1991-11-19 |
Cetus Corporation |
Combination therapy of IL-2 and DTIC for the treatment of melanoma
|
|
US4902502A
(en)
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
US5153310A
(en)
|
1989-02-28 |
1992-10-06 |
Du Pont Merck Pharmaceutical Company |
Il-2 analogs containing n-linked glycosylation sites
|
|
NZ234674A
(en)
|
1989-08-02 |
1992-02-25 |
Seragen Inc |
Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
|
|
US5660827A
(en)
|
1992-03-05 |
1997-08-26 |
Board Of Regents, The University Of Texas System |
Antibodies that bind to endoglin
|
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
|
EP0840622A4
(en)
|
1995-07-21 |
2003-01-02 |
Aventis Pharma Inc |
ADENO-ASSOCIATED VIRUS LIPOSOMES AND THEIR USE FOR THE TRANSFECTION OF DENDRITIC CELLS FOR THE STIMULATION OF SPECIFIC IMMUNITY
|
|
US20040115128A1
(en)
|
1995-09-08 |
2004-06-17 |
Schnitzer Jan E. |
Targeting endothelium for tissue-specific delivery of agents
|
|
EP1442750B1
(en)
|
1997-11-20 |
2012-08-01 |
Vical Incorporated |
Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
|
|
EP1987845B1
(en)
|
1997-11-20 |
2012-03-21 |
Vical Incorporated |
Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor.
|
|
US6232287B1
(en)
|
1998-03-13 |
2001-05-15 |
The Burnham Institute |
Molecules that home to various selected organs or tissues
|
|
US6455677B1
(en)
|
1998-04-30 |
2002-09-24 |
Boehringer Ingelheim International Gmbh |
FAPα-specific antibody with improved producibility
|
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
|
US6955807B1
(en)
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
|
US7138103B2
(en)
|
1998-06-22 |
2006-11-21 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
|
AU5728999A
(en)
|
1998-07-28 |
2000-02-21 |
Micromet Ag |
Heterominibodies
|
|
US6294349B1
(en)
|
1999-03-01 |
2001-09-25 |
University Of Mississippi Medical Ctr. |
Method of diagnosing and monitoring malignant breast carcinomas
|
|
US6348192B1
(en)
|
1999-05-11 |
2002-02-19 |
Bayer Corporation |
Interleukin-2 mutein expressed from mammalian cells
|
|
ATE464062T1
(de)
|
1999-10-04 |
2010-04-15 |
Novartis Vaccines & Diagnostic |
Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
|
|
WO2001053354A2
(en)
*
|
2000-01-20 |
2001-07-26 |
Chiron Corporation |
Methods for treating tumors using a fusion protein comprising il-2- polypeptides and p185-specific binding molecules
|
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
US6579521B2
(en)
|
2000-10-20 |
2003-06-17 |
Chiron Corporation |
Methods of therapy for HIV infection
|
|
CA2446087C
(en)
*
|
2001-05-03 |
2013-06-18 |
Stephen D. Gillies |
Recombinant tumor specific antibody and use thereof
|
|
CA2449517A1
(en)
|
2001-06-08 |
2002-12-19 |
Utah Ventures Ii, L.P. |
Tissue-specific endothelial membrane proteins
|
|
EP1476180A4
(en)
|
2001-08-13 |
2005-04-20 |
Univ Southern California |
MUTANTS OF INTERLEUKIN-2 WITH REDUCED TOXICITY
|
|
US20020187512A1
(en)
|
2001-09-10 |
2002-12-12 |
Nagem Ronaldo Alves Pinto |
Crystal structure of human interleukin-22
|
|
BR0214650A
(pt)
|
2001-12-04 |
2005-05-03 |
Merck Patent Gmbh |
Imunocitoquinas com seletividade modulada
|
|
EP1576112B1
(en)
|
2002-01-18 |
2012-02-29 |
ZymoGenetics, Inc. |
Cytokine receptor zcytor17 multimers
|
|
DE60332358D1
(de)
|
2002-09-09 |
2010-06-10 |
Hanall Pharmaceutical Co Ltd |
Protease-resistente modifizierte interferon alpha polypeptide
|
|
WO2004041862A2
(en)
|
2002-11-08 |
2004-05-21 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
WO2004081049A1
(en)
|
2003-03-10 |
2004-09-23 |
Auckland Uniservices Limited |
Monoclonal antibodies that recognise mucosal addressin cell adhesion molecule-1 (madcam-1), soluble madcam-1 and uses thereof
|
|
WO2005007121A2
(en)
|
2003-07-18 |
2005-01-27 |
Massachusetts Institute Of Technology |
Mutant interleukin-2(il-2) polypeptides
|
|
ATE500267T1
(de)
|
2003-07-21 |
2011-03-15 |
Transgene Sa |
Multifunktionelle cytokine
|
|
DE602004031341D1
(de)
|
2003-07-21 |
2011-03-24 |
Transgene Sa |
Multifunktionelle cytokine
|
|
KR100632985B1
(ko)
|
2003-07-26 |
2006-10-11 |
메덱스젠 주식회사 |
생리활성 조절 단백질의 효능 향상 방법 및 그 예시변이체들
|
|
US20050069521A1
(en)
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
|
US8454963B2
(en)
|
2003-11-13 |
2013-06-04 |
Musc Foundation For Research Development |
Tissue targeted complement modulators
|
|
CA2550998A1
(en)
|
2003-12-22 |
2005-07-14 |
Chiron Corporation |
Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders
|
|
SI2177537T1
(sl)
*
|
2004-01-09 |
2012-01-31 |
Pfizer |
Protitielesa proti MAdCAM
|
|
WO2005091956A2
(en)
|
2004-03-05 |
2005-10-06 |
Chiron Corporation |
In vitro test system for predicting patient tolerability of therapeutic agents
|
|
JP4773434B2
(ja)
|
2004-05-19 |
2011-09-14 |
イムノコア リミテッド |
高親和性ｎｙ−ｅｓｏｔ細胞受容体
|
|
US8815235B2
(en)
|
2004-06-02 |
2014-08-26 |
Jan E. Schnitzer |
Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
|
|
MX2007009012A
(es)
|
2005-01-27 |
2007-09-14 |
Novartis Vaccines & Diagnostic |
Metodos para tratar carcinoma de celulas renales.
|
|
EP1848454A1
(en)
|
2005-02-15 |
2007-10-31 |
Novartis Vaccines and Diagnostics, Inc. |
Methods for treating lymphomas using a combination of a chemotherapeutic agent and il-2 and optionally an anti-cd20 antibody
|
|
WO2006096461A2
(en)
|
2005-03-08 |
2006-09-14 |
Pharmacia & Upjohn Company Llc |
Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
|
|
ES2720160T3
(es)
|
2005-05-09 |
2019-07-18 |
Ono Pharmaceutical Co |
Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
|
|
EP3263581B2
(en)
|
2005-05-17 |
2025-07-09 |
University of Connecticut |
Compositions and methods for immunomodulation in an organism
|
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
|
ES2395969T3
(es)
|
2006-03-24 |
2013-02-18 |
Merck Patent Gmbh |
Dominios de proteínas heterodiméricas genéticamente modificados
|
|
EA018030B1
(ru)
|
2006-06-06 |
2013-05-30 |
Круселл Холланд Б.В. |
Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
|
|
CA2656700A1
(en)
|
2006-07-06 |
2008-01-10 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
|
|
WO2008085987A2
(en)
|
2007-01-09 |
2008-07-17 |
The Trustees Of The University Of Pennsylvania |
Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display
|
|
US8298545B2
(en)
|
2007-02-07 |
2012-10-30 |
The Trustees Of The University Of Pennsylvania |
Anti-autoimmune antibodies for treatment of pemphigus
|
|
US8354110B2
(en)
|
2007-03-07 |
2013-01-15 |
Uti Limited Partnership |
Compositions and methods for the prevention and treatment of autoimmune conditions
|
|
WO2008124858A2
(en)
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Targeted receptor
|
|
US20080260820A1
(en)
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
|
US8846867B2
(en)
|
2007-06-26 |
2014-09-30 |
The Trustees Of The University Of Pennsylvania |
Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
|
|
WO2009061853A2
(en)
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
|
CA2742926A1
(en)
|
2007-11-28 |
2009-06-04 |
Universite De Montreal |
Pd-1 modulation and uses thereof
|
|
DE102008023820A1
(de)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
US8927697B2
(en)
|
2008-09-12 |
2015-01-06 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
AU2009290543B2
(en)
|
2008-09-12 |
2015-09-03 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
BRPI0920749A8
(pt)
|
2008-10-02 |
2017-12-12 |
Emergent Product Dev Seattle |
Proteínas de ligação de antagonista multialvo cd86
|
|
US8343497B2
(en)
|
2008-10-12 |
2013-01-01 |
The Brigham And Women's Hospital, Inc. |
Targeting of antigen presenting cells with immunonanotherapeutics
|
|
KR20110086101A
(ko)
|
2008-10-21 |
2011-07-27 |
메르크 파텐트 게엠베하 |
방사선 및 면역사이토카인으로의 암 치료
|
|
AU2010206840B2
(en)
*
|
2009-01-21 |
2015-02-05 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
WO2010117423A2
(en)
|
2009-03-31 |
2010-10-14 |
Duke University |
A METHOD FOR TREATING A PATIENT HAVING OR AT RISK FOR DEVELOPING A DISORDER ASSOCIATED WITH DECREASED EXPRESSION OF ß2 ADRENERGIC RECEPTORS OR NEED FOR INCREASED ß2 ADRENERGIC RECEPTOR ACTIVITY
|
|
NZ714757A
(en)
|
2009-08-14 |
2018-07-27 |
Us Gov Health & Human Services |
Use of il-15 to increase thymic output and to treat lymphopenia
|
|
CU23734A1
(es)
|
2009-11-27 |
2011-11-15 |
Centro Inmunologia Molecular |
Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
|
|
SG181952A1
(en)
|
2009-12-29 |
2012-07-30 |
Emergent Product Dev Seattle |
Heterodimer binding proteins and uses thereof
|
|
ES2993335T3
(en)
|
2010-03-10 |
2024-12-27 |
Genmab As |
Monoclonal antibodies against c-met
|
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
CA2791930A1
(en)
|
2010-03-11 |
2011-09-15 |
Kerry Louise Tyson |
Pd-1 antibody
|
|
AU2011325833C1
(en)
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
HRP20210642T1
(hr)
|
2010-11-12 |
2021-05-28 |
Nektar Therapeutics |
Konjugati il-2 ostatka i polimera
|
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
JP6093712B2
(ja)
|
2010-12-22 |
2017-03-08 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
インターロイキン２のスーパーアゴニストおよびアンタゴニスト
|
|
US9266938B2
(en)
|
2011-02-10 |
2016-02-23 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
US20120207733A1
(en)
|
2011-02-14 |
2012-08-16 |
Allergan, Inc. |
Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases
|
|
AU2012222833B2
(en)
|
2011-03-03 |
2017-03-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
|
WO2012119093A1
(en)
|
2011-03-03 |
2012-09-07 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
DK2683395T3
(en)
|
2011-03-11 |
2018-11-19 |
Hopitaux Paris Assist Publique |
USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES
|
|
ES2811624T3
(es)
|
2011-03-11 |
2021-03-12 |
Hopitaux Paris Assist Publique |
Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US20140213459A1
(en)
|
2011-05-27 |
2014-07-31 |
Roland Beckmann |
Antibodies with improved folding stability
|
|
CA2840409A1
(en)
|
2011-06-28 |
2013-01-03 |
Whitehead Institute For Biomedical Research |
Using sortases to install click chemistry handles for protein ligation
|
|
EP3939613A1
(en)
|
2011-08-11 |
2022-01-19 |
ONO Pharmaceutical Co., Ltd. |
Therapeutic agent for autoimmune diseases comprising pd-1 agonist
|
|
WO2013043529A1
(en)
|
2011-09-19 |
2013-03-28 |
Emory University |
Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
|
|
AU2012332021B8
(en)
|
2011-11-04 |
2017-10-12 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
EP2780364A2
(en)
|
2011-11-18 |
2014-09-24 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
|
KR20180137614A
(ko)
|
2012-04-27 |
2018-12-27 |
노보 노르디스크 에이/에스 |
사람 cd30 리간드 항원 결합 단백질
|
|
WO2013177187A2
(en)
|
2012-05-22 |
2013-11-28 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
|
|
WO2013189516A1
(en)
|
2012-06-18 |
2013-12-27 |
Apeiron Biologics Ag |
Method for treating a gd2 positive cancer
|
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
US9943574B2
(en)
|
2012-06-27 |
2018-04-17 |
Arthrogen B.V. |
Combination for treating an inflammatory disorder
|
|
JP6498601B2
(ja)
|
2012-07-13 |
2019-04-10 |
ザイムワークス，インコーポレイテッド |
多価ヘテロ多量体足場設計および構築物
|
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
CN104662045B
(zh)
|
2012-08-07 |
2019-04-05 |
罗切格利卡特公司 |
包含两种工程化改造成具有降低的和升高的效应器功能的抗体的组合物改进的免疫疗法
|
|
CA2893981C
(en)
|
2012-12-05 |
2021-11-16 |
Shiow-Her Chiou |
Chemokine-cytokine fusion protein and its use
|
|
WO2014100014A1
(en)
|
2012-12-17 |
2014-06-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Super-2 complexes with antibody to augment il-2 therapy
|
|
US9657082B2
(en)
|
2013-01-31 |
2017-05-23 |
Thomas Jefferson University |
PD-L1 and PD-L2-based fusion proteins and uses thereof
|
|
US20150259416A1
(en)
|
2014-03-12 |
2015-09-17 |
Biocrine Ab |
Methods for treating and/or limiting development of diabetes
|
|
US9546203B2
(en)
*
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
|
CA2902905A1
(en)
|
2013-03-15 |
2014-09-25 |
Claude Geoffrey Davis |
Modified toxins
|
|
EP3424530A1
(en)
*
|
2013-03-15 |
2019-01-09 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
AU2014262469B2
(en)
|
2013-05-10 |
2019-11-14 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
|
US10611830B2
(en)
|
2013-06-06 |
2020-04-07 |
Hefei Lifeon Pharmaceutical Co. Ltd. |
Human antibody against ED-B domain of fibronectin and uses thereof
|
|
WO2015066543A1
(en)
|
2013-11-01 |
2015-05-07 |
Board Of Regents, The University Of Texas System |
Targeting her2 and her3 with bispecific antibodies in cancerous cells
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
CN111423513A
(zh)
|
2014-02-06 |
2020-07-17 |
豪夫迈·罗氏有限公司 |
白介素-2融合蛋白和其用途
|
|
EP3105333B1
(en)
|
2014-02-10 |
2020-04-08 |
Emory University |
Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
|
|
EP2918285A1
(en)
|
2014-03-11 |
2015-09-16 |
Université Pierre et Marie Curie (Paris 6) |
Interleukin-2 for treating food allergy
|
|
WO2015138435A1
(en)
|
2014-03-11 |
2015-09-17 |
Molecular Templates, Inc. |
Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
|
|
WO2015164815A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
|
US10815469B2
(en)
|
2014-06-11 |
2020-10-27 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties
|
|
EP2963057A1
(en)
|
2014-07-02 |
2016-01-06 |
Calypso Biotech SA |
Antibodies to IL-15
|
|
MX378790B
(es)
|
2014-07-21 |
2025-03-10 |
Delinia Inc |
Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
|
|
ES2743809T3
(es)
|
2014-07-31 |
2020-02-20 |
Amgen Res Munich Gmbh |
Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
|
|
US9982053B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
|
MA40094B1
(fr)
|
2014-08-06 |
2022-05-31 |
Univ Miami |
Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
|
|
SG11201700629TA
(en)
|
2014-08-11 |
2017-02-27 |
Delinia Inc |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
CA2957717C
(en)
|
2014-08-12 |
2021-10-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
|
WO2016030350A1
(en)
|
2014-08-29 |
2016-03-03 |
F. Hoffmann-La Roche Ag |
Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
|
|
HUE057605T2
(hu)
|
2014-10-23 |
2022-06-28 |
Singh Molecular Medicine Llc |
Intracelluláris antigének ellen irányuló egydoménes antitestek
|
|
EP3875152B1
(en)
|
2014-12-15 |
2024-04-10 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
|
CA3175979A1
(en)
|
2014-12-22 |
2016-06-30 |
Pd-1 Acquisition Group, Llc |
Anti-pd-1 antibodies
|
|
US20160206666A1
(en)
|
2014-12-22 |
2016-07-21 |
Synlogic, Inc. |
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
|
|
CA2916283C
(en)
*
|
2015-01-09 |
2024-07-02 |
Pfizer Inc. |
MADCAM ANTAGONIST DOSING REGIMEN
|
|
WO2016115168A1
(en)
|
2015-01-12 |
2016-07-21 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
AU2016233495B2
(en)
|
2015-03-13 |
2022-02-24 |
Cytomx Therapeutics, Inc |
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
|
|
US10059774B2
(en)
|
2015-04-08 |
2018-08-28 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind CD38
|
|
WO2016170176A1
(en)
|
2015-04-22 |
2016-10-27 |
Curevac Ag |
Rna containing composition for treatment of tumor diseases
|
|
EP3292140B1
(en)
|
2015-05-05 |
2022-04-20 |
Rubicon Biotechnology LLC |
Cancer immunotherapeutic
|
|
GB201507908D0
(en)
|
2015-05-08 |
2015-06-24 |
Philogen Spa |
IL2 and TNF immunoconjugates
|
|
CN114425077A
(zh)
|
2015-05-18 |
2022-05-03 |
起源生物医药公司 |
Sirp多肽组合物和使用方法
|
|
EP4272757A3
(en)
|
2015-06-10 |
2023-12-27 |
ImmunityBio, Inc. |
Modified nk-92 cells for treating cancer
|
|
EP3313883B1
(en)
|
2015-06-23 |
2023-12-06 |
Memorial Sloan Kettering Cancer Center |
Novel pd-1 immune modulating agents
|
|
IL256445B2
(en)
|
2015-06-30 |
2023-03-01 |
Nanotics Llc |
Compositions and methods related to absorbent particles
|
|
KR20180034619A
(ko)
|
2015-07-29 |
2018-04-04 |
나노틱스 엘엘씨 |
가용성 생체분자를 소거하기 위한 모듈 조성물 및 이와 관련된 방법
|
|
WO2017023780A1
(en)
|
2015-07-31 |
2017-02-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-drug conjugates for targeting cd56-positive tumors
|
|
JP2018527350A
(ja)
|
2015-09-01 |
2018-09-20 |
イミュンワーク インク．Ｉｍｍｕｎｗｏｒｋ Ｉｎｃ． |
血餅形成の予防及び／又は血栓症の治療のための分子構築物
|
|
KR102739782B1
(ko)
|
2015-09-11 |
2024-12-09 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
생물학적으로 관련된 직교 사이토카인/수용체 쌍
|
|
US10358497B2
(en)
|
2015-09-29 |
2019-07-23 |
Amgen Inc. |
Methods of treating cardiovascular disease with an ASGR inhibitor
|
|
HK1251158A1
(zh)
|
2015-09-29 |
2019-01-25 |
细胞基因公司 |
Pd-1结合蛋白及其使用方法
|
|
IL258844B2
(en)
|
2015-10-22 |
2024-03-01 |
Juno Therapeutics Gmbh |
Methods for culturing cells and kits and apparatus for same
|
|
CA3001429C
(en)
|
2015-10-22 |
2023-07-11 |
Iltoo Pharma |
Pharmaceutical compositions of il-2
|
|
KR102876923B1
(ko)
|
2015-10-23 |
2025-10-28 |
화이자 인코포레이티드 |
항-il-2 항체 및 조성물 및 이의 용도
|
|
WO2017070649A1
(en)
|
2015-10-23 |
2017-04-27 |
Junghans Richard P |
Combination methods for immunotherapy
|
|
EP3371311B1
(en)
|
2015-11-06 |
2021-07-21 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
|
PT3377103T
(pt)
|
2015-11-19 |
2021-05-26 |
Revitope Ltd |
Complementação de fragmento de anticorpo funcional para um sistema de dois componentes para exterminação redirecionada de células indesejadas
|
|
US10597466B2
(en)
|
2015-12-02 |
2020-03-24 |
Fred Hutchinson Cancer Research Center |
Circular tandem repeat proteins
|
|
WO2017096262A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
|
ES2901794T3
(es)
|
2015-12-09 |
2022-03-23 |
Hoffmann La Roche |
Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
|
|
WO2017102010A1
(en)
|
2015-12-17 |
2017-06-22 |
Biontech Rna Pharmaceuticals Gmbh |
Novel cytokine fusion proteins
|
|
WO2017107914A1
(zh)
|
2015-12-21 |
2017-06-29 |
合肥立方制药股份有限公司 |
一种药物设计方法和获得的药物及其应用
|
|
US11723932B2
(en)
|
2016-01-11 |
2023-08-15 |
Synlogic Operating Company, Inc. |
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
|
|
AU2017206618A1
(en)
|
2016-01-11 |
2018-07-05 |
Universität Zürich |
Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent
|
|
BR112018014150A2
(en)
|
2016-01-11 |
2018-12-11 |
Novartis Ag |
immunostimulating humanized monoclonal antibodies to human interleukin-2, and fusion proteins thereof
|
|
AU2017208153B2
(en)
|
2016-01-14 |
2021-01-28 |
Intrexon Actobiotics N.V. |
Compositions and methods for the treatment of type 1 diabetes
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
DK3411398T3
(da)
|
2016-02-05 |
2024-06-24 |
Orionis Biosciences BV |
Målrettede terapeutiske midler og anvendelse heraf
|
|
JP7220458B2
(ja)
|
2016-02-05 |
2023-02-10 |
ワシントン・ユニバーシティ |
標的サイトカインデリバリーのための組成物および方法
|
|
WO2017139570A1
(en)
|
2016-02-12 |
2017-08-17 |
Massachusetts Intitute Of Technology |
Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne
|
|
ES2718192T3
(es)
|
2016-02-25 |
2019-06-28 |
Provecs Medical Gmbh |
Sistema vector inmunoestimulante novedoso
|
|
JP7657014B2
(ja)
|
2016-03-07 |
2025-04-04 |
ブイアイビー ブイゼットダブリュー |
Ｃｄ２０結合単一ドメイン抗体
|
|
BR112018068055A2
(pt)
|
2016-03-10 |
2019-01-08 |
Univ Johns Hopkins |
métodos para produção de proteínas de fusão de toxina da difteria monoméricas livre de agregados e usos terapêuticas
|
|
CN108778316B
(zh)
|
2016-03-16 |
2023-07-04 |
谢彦晖 |
糖皮质激素联合聚乙二醇修饰的白介素2治疗呼吸道疾病
|
|
US11186641B2
(en)
|
2016-03-17 |
2021-11-30 |
Oslo Universitetssykehus Hf |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
|
AU2017249694B2
(en)
|
2016-04-12 |
2019-10-03 |
Philogen S.P.A. |
Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (CAR)-T cell
|
|
WO2017178569A1
(en)
|
2016-04-15 |
2017-10-19 |
Philogen S.P.A |
Non-glycosylated anti-tenascin antibody
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
CN109071623B
(zh)
|
2016-05-04 |
2022-05-27 |
美国安进公司 |
用于扩增t调节性细胞的白细胞介素-2突变蛋白
|
|
EP3453401A4
(en)
|
2016-05-06 |
2020-01-29 |
Wang, Mulin |
INTERLEUKIN COMBINATION AND USE THEREOF
|
|
GB201608192D0
(en)
|
2016-05-10 |
2016-06-22 |
Immunovia Ab |
Method, array and use thereof
|
|
EP3458485B1
(en)
|
2016-05-19 |
2021-12-29 |
The General Hospital Corporation |
Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
|
|
WO2017202786A1
(en)
|
2016-05-25 |
2017-11-30 |
F. Hoffmann-La Roche Ag |
Materials and methods relating to dosage regimen design
|
|
EP3463440A4
(en)
|
2016-05-27 |
2020-04-15 |
Etubics Corporation |
NEOEPITOP VACCINE COMPOSITIONS AND METHOD FOR USE THEREOF
|
|
EP3464560A4
(en)
|
2016-06-03 |
2020-01-15 |
Etubics Corporation |
TUMOR IMMUNOTHERAPY COMPOSITIONS AND METHODS INVOLVING HER2 / NEU
|
|
WO2017210649A1
(en)
|
2016-06-03 |
2017-12-07 |
Etubics Corporation |
Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseases
|
|
JP6983819B2
(ja)
|
2016-06-03 |
2021-12-17 |
エトゥビクス コーポレーション |
前立腺がん関連抗原を使用する腫瘍ワクチン接種用の組成物及び方法
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
IL263874B2
(en)
|
2016-06-22 |
2025-02-01 |
David Klatzmann |
Genetically modified T lymphocytes
|
|
US11141463B2
(en)
|
2016-07-11 |
2021-10-12 |
The National Institute for Biotechnology in the Negev Ltd. |
Fusion proteins with extended serum half life
|
|
EP3484508A4
(en)
|
2016-07-15 |
2020-03-25 |
Etubics Corporation |
COMPOSITIONS AND METHODS FOR VACCINATION AGAINST ALPHAVIRUSES
|
|
CN109843323B
(zh)
|
2016-07-15 |
2022-06-07 |
埃特彼塞斯公司 |
用于黄病毒疫苗接种的组合物和方法
|
|
GB201614093D0
(en)
|
2016-08-17 |
2016-09-28 |
Autolus Ltd |
Vector
|
|
CA3033788A1
(en)
|
2016-08-17 |
2018-02-22 |
Factor Bioscience Inc. |
Nucleic acid products and methods of administration thereof
|
|
AU2017312121A1
(en)
|
2016-08-19 |
2019-03-21 |
Brooklyn Immunotherapeutics Llc |
Uses of PD-1/PD-L1 inhibitors and/or CTLA-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
|
|
JP2020501508A
(ja)
|
2016-09-15 |
2020-01-23 |
クアドルセプト バイオ リミテッド |
多量体、四量体および八量体
|
|
AU2017329024A1
(en)
|
2016-09-19 |
2019-03-21 |
Celgene Corporation |
Methods of treating immune disorders using pd-1 binding proteins
|
|
WO2018053401A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating vitiligo using pd-1 binding proteins
|
|
US11673971B2
(en)
|
2016-09-23 |
2023-06-13 |
Marengo Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
|
KR20190049887A
(ko)
|
2016-09-29 |
2019-05-09 |
난트케이웨스트, 인크. |
감소된 면역원성을 갖는 hla 클래스 i-결핍 nk-92 세포
|
|
WO2018089420A1
(en)
|
2016-11-08 |
2018-05-17 |
Delinia, Inc. |
Il-2 variants for the treatment of autoimmune diseases
|
|
US20190275133A1
(en)
|
2016-11-10 |
2019-09-12 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method
|
|
US10011269B2
(en)
|
2016-11-30 |
2018-07-03 |
Ford Global Technologies, Llc |
Identifying in-range fuel pressure sensor error
|
|
CN110177564A
(zh)
|
2016-12-13 |
2019-08-27 |
德里尼亚公司 |
多价的调节t细胞调节剂
|
|
AU2017375460A1
(en)
|
2016-12-15 |
2019-07-04 |
The Brigham And Women's Hospital, Inc. |
Tissue-based biologics for the treatment of inflammatory and autoimmune disorders
|
|
MX2019007611A
(es)
|
2016-12-22 |
2020-07-29 |
Cue Biopharma Inc |
Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
|
|
US10232053B2
(en)
|
2016-12-30 |
2019-03-19 |
Trieza Therapeutics, Inc. |
Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
|
|
US11065345B2
(en)
|
2017-01-04 |
2021-07-20 |
Nanotics, Llc |
Methods for assembling scavenging particles
|
|
WO2018129188A1
(en)
|
2017-01-04 |
2018-07-12 |
Nanotics, Llc |
Methods for assembling scavenging particles
|
|
EP3565889B1
(en)
|
2017-01-06 |
2025-03-26 |
ImmunityBio, Inc. |
Genetically modified nk-92 cells with decreased cd96/tigit expression
|
|
JP7780248B2
(ja)
|
2017-01-06 |
2025-12-04 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍壊死因子受容体スーパーファミリー（ｔｎｆｒｓｆ）アゴニストによる腫瘍浸潤リンパ球（ｔｉｌ）の拡大培養及びｔｉｌとｔｎｆｒｓｆアゴニストとの治療的併用
|
|
WO2018132516A1
(en)
|
2017-01-10 |
2018-07-19 |
Nodus Therapeutics |
Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
|
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
|
US12350303B2
(en)
|
2017-02-03 |
2025-07-08 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Oncolytic virus therapy
|
|
PT3583125T
(pt)
|
2017-02-16 |
2025-04-04 |
Sonnet Biotherapeutics Inc |
Proteínas de fusão ao domínio de ligação à albumina
|
|
US11318164B2
(en)
|
2017-03-01 |
2022-05-03 |
Nektar Therapeutics |
Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy
|
|
EP3596108A4
(en)
|
2017-03-15 |
2020-12-23 |
Pandion Operations, Inc. |
TARGETED IMMUNOTOLERANCE
|
|
CN118453840A
(zh)
|
2017-03-15 |
2024-08-09 |
库尔生物制药有限公司 |
用于调节免疫应答的方法
|
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
EP3606947B1
(en)
|
2017-04-03 |
2022-12-21 |
F. Hoffmann-La Roche AG |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
|
KR20190121816A
(ko)
|
2017-04-03 |
2019-10-28 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
CN108686202A
(zh)
|
2017-04-06 |
2018-10-23 |
张晋宇 |
肿瘤免疫疗法
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
JP2020516638A
(ja)
|
2017-04-13 |
2020-06-11 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを処置する方法における使用のための、インターロイキン２イムノコンジュゲート、ｃｄ４０アゴニスト、および任意選択のｐｄ−１軸結合アンタゴニスト
|
|
US11274141B2
(en)
|
2017-05-10 |
2022-03-15 |
Wellstat Immunotherapeutics, Llc |
Enveloped virus resistant to complement inactivation for the treatment of cancer
|
|
JP7349365B2
(ja)
|
2017-05-10 |
2023-09-22 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
液性腫瘍からの腫瘍浸潤リンパ球の拡大培養及びその治療的使用
|
|
US11913962B2
(en)
|
2017-05-15 |
2024-02-27 |
University Of Miami |
Materials and methods for subjects at risk for viral reactivation
|
|
CN111107868A
(zh)
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
抗体细胞因子移植蛋白及使用方法
|
|
AU2018273914A1
(en)
|
2017-05-24 |
2019-11-14 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
|
IL322309A
(en)
|
2017-05-24 |
2025-09-01 |
Novartis Ag |
IL2 antibody grafted proteins and methods of use in cancer treatment
|
|
US20210277085A1
(en)
|
2017-05-24 |
2021-09-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
AR112072A1
(es)
|
2017-06-05 |
2019-09-18 |
Iovance Biotherapeutics Inc |
Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
|
|
CN110891605A
(zh)
|
2017-06-07 |
2020-03-17 |
希沃尔拜克治疗公司 |
免疫调节化合物的抗体缀合物及其用途
|
|
US11241485B2
(en)
|
2017-06-12 |
2022-02-08 |
Obsidian Therapeutics, Inc. |
PDE5 compositions and methods for immunotherapy
|
|
US11845806B2
(en)
|
2017-06-14 |
2023-12-19 |
Dingfu Biotarget Co., Ltd. |
Proteinaceous heterodimer and use thereof
|
|
JP7433051B2
(ja)
|
2017-06-19 |
2024-02-19 |
メディシナ セラピューティクス インコーポレイテッド |
Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
EP3648786A4
(en)
|
2017-07-03 |
2021-12-15 |
Torque Therapeutics, Inc. |
FUSION MOLECULES TARGETING IMMUNE REGULATORY CELLS AND THEIR USES
|
|
CN111246865A
(zh)
|
2017-07-12 |
2020-06-05 |
同生运营公司 |
程序化以在肿瘤细胞中产生免疫调节剂和抗癌治疗剂的微生物
|
|
US20190023760A1
(en)
|
2017-07-24 |
2019-01-24 |
Eth Zurich |
Method for preparing interleukin-2 or interleukin-2 analogues
|
|
MA49767A
(fr)
|
2017-08-03 |
2021-05-26 |
Synthorx Inc |
Conjugués de cytokine pour le traitement de maladies auto-immunes
|
|
WO2019025545A1
(en)
|
2017-08-04 |
2019-02-07 |
Genmab A/S |
BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
|
|
WO2019032663A1
(en)
|
2017-08-09 |
2019-02-14 |
Orionis Biosciences Inc. |
PD-1 AND PD-L1 BINDING AGENTS
|
|
JP7327885B2
(ja)
|
2017-08-09 |
2023-08-16 |
オリオンズ バイオサイエンス インコーポレイテッド |
Ｃｌｅｃ９ａ結合物質およびその使用
|
|
CA3069930A1
(en)
|
2017-08-09 |
2019-02-14 |
Orionis Biosciences Inc. |
Cd8 binding agents
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
MX2020001879A
(es)
|
2017-08-18 |
2020-07-29 |
Gritstone Oncology Inc |
Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
|
|
WO2019046815A1
(en)
|
2017-08-31 |
2019-03-07 |
Poseida Therapeutics, Inc. |
TRANSPOSON SYSTEM AND METHODS OF USE
|
|
AU2018328283A1
(en)
|
2017-09-07 |
2020-02-20 |
Cue Biopharma, Inc. |
Antigen-presenting polypeptides and methods of use thereof
|
|
CA3074839A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
|
|
WO2019051126A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF
|
|
BR112020004535A2
(pt)
|
2017-09-07 |
2020-09-08 |
Cue Biopharma, Inc. |
peptídeos moduladores de células t multiméricos e métodos de uso destes
|
|
EP3679145A2
(en)
|
2017-09-08 |
2020-07-15 |
Poseida Therapeutics, Inc. |
Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
|
|
AU2018338608B2
(en)
|
2017-09-27 |
2025-09-11 |
Sigilon Therapeutics, Inc. |
Methods, compositions, and implantable elements comprising active cells
|
|
WO2019062877A1
(zh)
|
2017-09-30 |
2019-04-04 |
合肥立方制药股份有限公司 |
结合至纤维连接蛋白b结构域的蛋白
|
|
US11474271B2
(en)
|
2017-10-24 |
2022-10-18 |
Schlumberger Technology Corporation |
Methods and systems for automated sonic imaging
|
|
WO2019084284A1
(en)
|
2017-10-27 |
2019-05-02 |
Coneksis, Inc. |
NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS
|
|
KR102771546B1
(ko)
|
2017-11-08 |
2025-02-21 |
야페이 상하이 바이오로지 메디신 사이언스 앤드 테크놀로지 컴퍼니 리미티드 |
생체분자의 컨쥬게이트 및 이의 용도
|
|
JP2021502422A
(ja)
|
2017-11-13 |
2021-01-28 |
エクストレモチェム・エルディーエー．Ｅｘｔｒｅｍｏｃｈｅｍ，Ｌｄａ． |
生体分子の安定剤としての中性のグリコシル化されたアミド及びジアニオン性のグルクロン酸化された酸
|
|
CN111601883B
(zh)
|
2017-11-17 |
2024-06-21 |
艾欧凡斯生物治疗公司 |
由细针抽吸物和小活检物扩增til
|
|
US20200299349A1
(en)
|
2017-11-21 |
2020-09-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Partial agonists of interleukin-2
|
|
JP2021503885A
(ja)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養
|
|
EP3720871A4
(en)
|
2017-12-06 |
2021-09-15 |
Pandion Operations, Inc. |
TARGETED IMMUNOTOLERANCE
|
|
US11780899B2
(en)
|
2017-12-06 |
2023-10-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Engineered proteins to enhance sensitivity of a cell to IL-2
|
|
BR112020011343A2
(pt)
|
2017-12-06 |
2020-11-17 |
Pandion Therapeutics, Inc. |
muteínas de il-2 e seus usos
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
CN111479917A
(zh)
|
2017-12-13 |
2020-07-31 |
詹森生物科技公司 |
经基因修饰以消除T细胞受体和β2-微球蛋白表达的永生化CAR-T细胞
|
|
WO2019118873A2
(en)
|
2017-12-15 |
2019-06-20 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
EP3728314A1
(en)
|
2017-12-19 |
2020-10-28 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
EP3728302A1
(en)
|
2017-12-19 |
2020-10-28 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
|
EP3502139A1
(en)
|
2017-12-19 |
2019-06-26 |
Philogen S.p.A. |
Antibodies to tumour antigens
|
|
CN112218885B
(zh)
|
2017-12-20 |
2024-06-18 |
波赛达治疗公司 |
Vcar组合物和使用方法
|
|
JP7336457B2
(ja)
|
2017-12-26 |
2023-08-31 |
ナンジン、ジェンスクリプト、バイオテック、カンパニー、リミテッド |
抗体Ｆｃ領域を主鎖として用いた融合タンパク質二量体及びその使用
|
|
KR102740971B1
(ko)
|
2017-12-27 |
2024-12-11 |
쿄와 기린 가부시키가이샤 |
Il-2 개변체
|
|
US20210079106A1
(en)
|
2017-12-28 |
2021-03-18 |
Julius-Maximilians-Universität Würzburg |
TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCgR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCgR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
US12104172B2
(en)
|
2018-01-08 |
2024-10-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific t-cells
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2019144309A1
(en)
|
2018-01-24 |
2019-08-01 |
Beijing Percans Oncology Co. Ltd. |
Cytokine Fusion Proteins
|
|
CN112105632A
(zh)
|
2018-01-24 |
2020-12-18 |
北京智康博药肿瘤医学研究有限公司 |
细胞因子融合蛋白
|
|
TWI708787B
(zh)
|
2018-03-02 |
2020-11-01 |
美商美國禮來大藥廠 |
Pd-1促效劑抗體及其用途
|
|
CA3092947A1
(en)
|
2018-03-07 |
2019-09-12 |
Poseida Therapeutics, Inc. |
Cartyrin compositions and methods for use
|
|
WO2019173832A2
(en)
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
WO2020014271A1
(en)
|
2018-07-09 |
2020-01-16 |
Surrozen, Inc. |
Tissue-specific wnt signal enhancing molecules and uses
|
|
JP7550745B2
(ja)
|
2018-07-24 |
2024-09-13 |
バイオエヌテック エスエー |
Ｉｌ２アゴニスト
|
|
US20220041713A1
(en)
|
2018-09-18 |
2022-02-10 |
Pandion Operations, Inc |
Targeted immunotolerance
|
|
GB2583560A
(en)
|
2018-12-11 |
2020-11-04 |
Admirx Inc |
Fusion protein constructs for complement associated disease
|
|
US20220106398A1
(en)
|
2019-02-08 |
2022-04-07 |
Igm Biosciences, Inc. |
Anti-gitr antigen-binding domains and uses thereof
|
|
TW202110885A
(zh)
|
2019-05-20 |
2021-03-16 |
美商潘迪恩治療公司 |
靶向ＭＡｄＣＡＭ之免疫耐受性
|
|
CN114728179A
(zh)
|
2019-08-19 |
2022-07-08 |
潘迪恩运营公司 |
利用pd-1激动剂的靶向免疫耐受
|
|
US11095944B2
(en)
|
2019-08-19 |
2021-08-17 |
Roku, Inc. |
Content-modification system with broadcast schedule utilization feature
|
|
WO2021168079A1
(en)
|
2020-02-21 |
2021-08-26 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a cd39 effector
|
|
EP4107189A4
(en)
|
2020-02-21 |
2024-07-03 |
Pandion Operations, Inc. |
TISSUE-TARGETED IMMUNOTOLERANCE WITH PD-1 AGONISTS OR IL-2 MUTEINS
|
|
CN116368155A
(zh)
|
2020-08-19 |
2023-06-30 |
潘迪恩运营公司 |
多互补位抗pd-1抗体及其用途
|
|
US20240262905A1
(en)
|
2020-10-16 |
2024-08-08 |
Pandion Operations, Inc. |
Skin targeted immunotolerance
|
|
WO2022082019A2
(en)
|
2020-10-16 |
2022-04-21 |
Pandion Operations, Inc. |
Kidney targeted immunotolerance
|